GoldenGolden
Incyte

Incyte

A global biopharmaceutical company focused on the discovery and development of small-molecule drugs.

Incyte is a global biopharmaceutical company, founded in 2002 in Wilmington, Delaware, by a team of research scientists, chemists and biologists working in immunology. The company has grown to employ over 1400 people and has operations in the U.S., Europe, and Japan. Incyte focuses on the discovery and development of small-molecule drugs.

The company has a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. They are advancing a growing pipeline of medicines across two franchises: Oncology and Inflammation & Autoimmunity.

Covid-19 Treatment

Clinical trials are testing the viability of Incyte drugs for the treatment of coronavirus. As of February 2020, Camrelizumab (humanized monoclonal antibody targeting PD-1) and thymosin are being used in two ongoing clinical trials.

Timeline

People

Name
Role
LinkedIn

Barry P. Flannelly

Executive Vice President, General Manager, US

Christiana Stamoulis

Executive Vice President and Chief Financial Officer

Dashyant Dhanak

Executive Vice President and Chief Scientific Officer

Herve Hoppenot

Chairman, President and Chief Executive Officer

Jonathan E. Dickinson

Executive Vice President and General Manager, Europe

Lothar H. Finke

Head of Clinical Development and General Manager, Japan

Maria E. Pasquale

Executive Vice President, General Counsel

Michael Morrissey

Executive Vice President and Head of Global Technical Operations

Paula J. Swain

Executive Vice President, Human Resources

Steven H. Stein

Executive Vice President, Chief Medical Officer

Vijay Iyengar

Executive Vice President, Global Strategy and Corporate Development

Wenqing Yao

Executive Vice President, Discovery Chemistry

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Innovent Biologics, Inc.
June 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
Eli Lilly & Company
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4...
Innovent Biologics, Inc.
May 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
Mark Terry
May 20, 2021
BioSpace
Companies have already begun their announcements of new clinical studies for various treatment settings in preparation for ASCO 2021.
Brandon May
May 17, 2021
BioSpace
The use of ruxolitinib cream, Incyte's investigational anti-inflammatory JAK inhibitor topical treatment, significantly improved facial vitiligo in adolescents and adults, according to topline results from two pivotal Phase III clinical trials.
Nick Paul
May 17, 2021
FierceBiotech
Phase 3 trials of Incyte's ruxolitinib cream in patients with vitiligo have met their primary endpoints. The success of the topical JAK inhibitor tees Incyte up to seek approval in the U.S. and Europe in the second half of the year.
BioSpace
May 17, 2021
BioSpace
Incyte (Nasdaq:INCY) today announced positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream
Mark Terry
April 26, 2021
BioSpace
It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 arena. Here's a look.
Eli Lilly and Company
April 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company...
April 20, 2021
BioSpace
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study - read this article along with other careers information, tips and advice on BioSpace
April 19, 2021
BioSpace
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma - read this article along with other careers information, tips and advice on BioSpace
Mark Terry
April 8, 2021
BioSpace
Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.
BioSpace
April 8, 2021
BioSpace
Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death)
Brandon May
April 7, 2021
BioSpace
The action data was extended by the agency to provide more time to review new data analyses submitted by Lilly, per information requests made by the FDA.
Eli Lilly and Company; Incyte
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the...
Nick Paul
January 22, 2021
FierceBiotech
The FDA has accepted Incyte's PD-1 inhibitor retifanlimab for priority review in patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC).
Eli Lilly and Company
December 11, 2020
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published...
Innovent Biologics
December 8, 2020
www.prnewswire.com:443
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
December 4, 2020
BioSpace
Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease - read this article along with other careers information, tips and advice on BioSpace
Eli Lilly and Company
November 19, 2020
www.prnewswire.com:443
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.